GT Biopharma, Inc.GTBPNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank38
Year-over-Year Change
Year-over-year operating cash flow growth rate
Latest
-9.36%
↑ 86% vs avg
Percentile
P38
Within normal range
Streak
2 qtr
Consecutive growthAccelerating
Average
-66.98%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -9.36% |
| Q3 2025 | -22.00% |
| Q2 2025 | -36.88% |
| Q1 2025 | 10.78% |
| Q4 2024 | 9.83% |
| Q3 2024 | 22.60% |
| Q2 2024 | 15.06% |
| Q1 2024 | -103.37% |
| Q4 2023 | -4.23% |
| Q3 2023 | -1.50% |
| Q2 2023 | 33.41% |
| Q1 2023 | 32.39% |
| Q4 2022 | -47.29% |
| Q3 2022 | -4.74% |
| Q2 2022 | 46.58% |
| Q1 2022 | -40.76% |
| Q4 2021 | 5.70% |
| Q3 2021 | 8.37% |
| Q2 2021 | -16.40% |
| Q1 2021 | -91.18% |
| Q4 2020 | -13.29% |
| Q3 2020 | 50.13% |
| Q2 2020 | -1429.60% |
| Q1 2020 | 54.02% |
| Q4 2019 | 56.93% |
| Q3 2019 | -3.59% |
| Q2 2019 | -13.11% |
| Q1 2019 | 22.75% |
| Q4 2018 | 63.76% |
| Q3 2018 | -93.52% |
| Q2 2018 | 58.02% |
| Q1 2018 | -96.38% |
| Q4 2017 | 3.80% |
| Q3 2017 | -472.12% |
| Q2 2017 | 39.85% |
| Q1 2017 | -381.48% |
| Q4 2016 | 76.02% |
| Q3 2016 | 47.14% |
| Q2 2016 | -537.72% |
| Q1 2016 | 82.31% |